| 1 |
Cao Y, Xu P, Shen Y, Wu W, Chen M, Wang F, Zhu Y, Yan F, Gu W, Lin Y. Exosomes and cancer immunotherapy: A review of recent cancer research. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1118101] [Reference Citation Analysis]
|
| 2 |
Xia J, Li S, Liu S, Zhang L. Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets. MedComm (2020) 2023;4:e195. [PMID: 36694633 DOI: 10.1002/mco2.195] [Reference Citation Analysis]
|
| 3 |
Zhang Y, Chen J, Liu H, Mi R, Huang R, Li X, Fan F, Xie X, Ding J. The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1099892] [Reference Citation Analysis]
|
| 4 |
Kim JH, Lee CH, Baek MC. Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer. Exp Mol Med 2022;54:1833-43. [PMID: 36446847 DOI: 10.1038/s12276-022-00898-7] [Reference Citation Analysis]
|
| 5 |
Moreno-Andrés D, Holl K, Antonin W. The second half of mitosis and its implications in cancer biology. Semin Cancer Biol 2022;88:1-17. [PMID: 36436712 DOI: 10.1016/j.semcancer.2022.11.013] [Reference Citation Analysis]
|
| 6 |
Zhao L, Yu L, Wang X, He J, Zhu X, Zhang R, Yang A. Mechanisms of function and clinical potential of exosomes in esophageal squamous cell carcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215993] [Reference Citation Analysis]
|
| 7 |
Matsuzaka Y, Yashiro R. Molecular Docking and Intracellular Translocation of Extracellular Vesicles for Efficient Drug Delivery. IJMS 2022;23:12971. [DOI: 10.3390/ijms232112971] [Reference Citation Analysis]
|
| 8 |
Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol 2022;13:1016817. [DOI: 10.3389/fimmu.2022.1016817] [Reference Citation Analysis]
|
| 9 |
Gao Z, Ling X, Shi C, Wang Y, Lin A. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ Sci B 2022;23:823-43. [PMID: 36226537 DOI: 10.1631/jzus.B2200195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther 2022;7:353. [PMID: 36198685 DOI: 10.1038/s41392-022-01200-x] [Reference Citation Analysis]
|
| 11 |
Yang G, Liu Y, Ding L, Tao F, Zhu M, Shi Z, Wen J, Niu M, Li X, Xu Z, Qin W, Fei C, Chen J. A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance. Front Pharmacol 2022;13:989575. [DOI: 10.3389/fphar.2022.989575] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Yang C, Li D, Zang S, Zhang L, Zhong Z, Zhou Y. Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A. Front Pharmacol 2022;13:955218. [DOI: 10.3389/fphar.2022.955218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J, Wei S, Fan Q, Peng X, Li X, Zhang D, Yang L, Li H. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett 2022;:215823. [PMID: 35835409 DOI: 10.1016/j.canlet.2022.215823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
